SCHEMBL3094857

SCHEMBL3094857

CC1C(C)N1C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.53
HIF1A Q16665 1/20 0.48
CYP3A4 P08684 5/20 0.43
USP2 O75604 5/20 0.43
TSHR P16473 4/20 0.43
CYP2C19 P33261 1/20 0.43
CYP2C9 P11712 3/20 0.42
RHOC P08134 2/20 0.41
RHOA P61586 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
NOTUM Q6P988 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
HSD17B10 Q99714 1/20 0.39
HSD11B1 P28845 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3094854 1.00 CES2 (0.53) CES2HIF1ACYP3A4USP2TSHR
SCHEMBL3096904 0.79 CES2 (0.50) CES2HIF1ACYP3A4USP2TSHR
SCHEMBL3091750 0.77 CES2 (0.48) CES2HIF1ACYP3A4USP2TSHR
SCHEMBL13156507 0.76 CES2 (0.47) CES2HIF1ACYP3A4USP2TSHR
SCHEMBL3094810 0.75 CYP3A4 (0.47) CES2CYP3A4USP2TSHRCYP2C9
SCHEMBL3094820 0.75 CYP3A4 (0.47) CES2CYP3A4USP2TSHRCYP2C9
SCHEMBL13753509 0.73 HPGD (0.56) HIF1ACYP3A4USP2TSHRCYP2C19
SCHEMBL30691966 0.72 HIF1A (0.46) CES2HIF1ACYP3A4USP2TSHR
SCHEMBL96116 0.71 CES2 (0.67) CES2HIF1ANOTUMGAAMAPT
SCHEMBL16180051 0.71 CES2 (0.73) CES2HIF1ANOTUMGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799934-B2 Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst UNIVERSITY OF SOUTH FLORIDA (US) 2010-09-21 US disclosed
US-20090030212-A1 Enantioselective ring-opening of aziridines UNIVERSITY OF SOUTH FLORIDA OF TAMPA 2009-01-29 US disclosed
WO-2009005775-A2 ENANTIOSELECTIVE RING-OPENING OF AZIRIDINES UNIVERSITY OF SOUTH FLORIDA (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030212-A1 Enantioselective ring-opening of aziridines AZI2, ITPA, ADORA2A CES2 3526/4885HIF1A 4306/4885CYP3A4 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.